A Career Development Program will be a major and essential part of this proposed SPORE. Its goal will be to develop physicians, basic and population scientists for lifelong productive careers in translational prostate cancer research. The program will strive to make these individuals scientifically productive, academically successful and influential nationally, and good role models for recruitment of individuals to similar careers.The program will involve all of the institutions within the SPORE: in Seattle, the Fred Hutchinson CancerResearch Center (FHCRC), and the University of Washington (UW); in Vancouver, the University of BritishColumbia (UBC) and Prostate Center at the Vancouver General Hospital (VGH); and, in Portland the OregonHealth Sciences University (OHSU). The coordination between the three areas will involve recruitment,development and educational opportunities, and the interchange of mentors and research opportunities. Thespecific goals of this program are to:1. Recruit and train four to seven post-doctoral fellows in prostate cancer translational research per year;2. Recruit and nurture one to two faculty members at each institution whose main interest is prostate cancer translational research every 2-3 years;3. Enhance and develop a broad program of education and mentoring within the SPORE environment. This educational program will involve not only a large spectrum of individual research opportunities, but also a more formal educational experience of didactic courses and a large number of scheduled conferences and seminars.Recruitment of fellows and junior faculty will occur through the planned educational program and bysystematic recruitment efforts. These individuals will be monitored and mentored by a specific CareerDevelopment committee, and by 47 multidisciplinary investigators at these institutions both within andoutside the SPORE whose research interests and accomplishments reflect prostate cancer researchconcerns. In addition to SPORE grant support, this program will be supported by extensive institutionalresources.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA097186-06
Application #
7314963
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (M1))
Project Start
2007-07-01
Project End
2012-06-30
Budget Start
2007-09-14
Budget End
2008-06-30
Support Year
6
Fiscal Year
2007
Total Cost
$156,067
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Beshiri, Michael L; Tice, Caitlin M; Tran, Crystal et al. (2018) A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic Screening. Clin Cancer Res 24:4332-4345
Das, Lipsa; Gard, Jaime M C; Prekeris, Rytis et al. (2018) Novel Regulation of Integrin Trafficking by Rab11-FIP5 in Aggressive Prostate Cancer. Mol Cancer Res 16:1319-1331
Dai, James Y; Wang, Bo; Wang, Xiaoyu et al. (2018) Vigorous physical activity is associated with metastatic-lethal progression in prostate cancer and differential tumor DNA methylation in the CRACR2A gene. Cancer Epidemiol Biomarkers Prev :
Mateo, Joaquin; Cheng, Heather H; Beltran, Himisha et al. (2018) Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study. Eur Urol 73:687-693
Lim, Daniel M; Gulati, Roman; Aleshin-Guendel, Serge et al. (2018) Undetectable prostate-specific antigen after short-course androgen deprivation therapy for biochemically recurrent patients correlates with metastasis-free survival and prostate cancer-specific survival. Prostate :
Sehrawat, Archana; Gao, Lina; Wang, Yuliang et al. (2018) LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A 115:E4179-E4188
FitzGerald, L M; Zhao, S; Leonardson, A et al. (2018) Germline variants in IL4, MGMT and AKT1 are associated with prostate cancer-specific mortality: An analysis of 12,082 prostate cancer cases. Prostate Cancer Prostatic Dis 21:228-237
Lee, Chung C W; Munuganti, Ravi Shashi Nayana; Peacock, James W et al. (2018) Targeting Semaphorin 3C in Prostate Cancer With Small Molecules. J Endocr Soc 2:1381-1394
Mostaghel, Elahe A (2018) Alternative Acts: Oncogenic Splicing of Steroidogenic Enzymes in Prostate Cancer. Clin Cancer Res :
Zhao, Shanshan; Leonardson, Amy; Geybels, Milan S et al. (2018) A five-CpG DNA methylation score to predict metastatic-lethal outcomes in men treated with radical prostatectomy for localized prostate cancer. Prostate :

Showing the most recent 10 out of 400 publications